Having trouble accessing articles? Reset your cache.

A first for Keytruda in triple-negative breast cancer

Nearly a decade after FDA drafted guidance to spur the development of new treatments for neoadjuvant triple-negative breast cancer, Merck’s Keytruda has shown

Read the full 236 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE